{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T07:16:00Z","timestamp":1783322160484,"version":"3.54.6"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008252","name":"Universit\u00e0 degli Studi di Udine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate visual and anatomical outcomes after switching to aflibercept 8\u00a0mg in eyes with neovascular age-related macular degeneration (nAMD), and to assess outcomes according to the clinical indication for switching.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Multicentre retrospective observational study including 300 eyes with nAMD previously treated with anti-vascular endothelial growth factor therapy and switched to aflibercept 8\u00a0mg for non-response (n:74, 24.7%), suboptimal response (n:159, 53.0%), or durability-driven reasons (n:67, 22.3%). Longitudinal data from the 6\u00a0months preceding the switch and post-switch visits at 3 and 6\u00a0months were analyzed. The primary outcome was change in best-corrected visual acuity (BCVA, ETDRS letters) from the switch visit to the 3-month post-switch visit. Secondary outcomes included changes in central subfield thickness (CST) and retinal fluid status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During the pre-switch period, mean BCVA declined by\u2009\u2212\u20091.9\u2009\u00b1\u20098.2 letters and CST increased. At 3\u00a0months after switching, BCVA improved by\u2009+\u20092.0\u2009\u00b1\u20099.2 letters (95% CI,\u2009+\u20090.8 to\u2009+\u20093.2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), with greater gains in eyes switched for non-response (+\u20092.8\u2009\u00b1\u200912.6 letters). Mean CST decreased by\u2009\u2212\u200945.3\u2009\u00b1\u200979.8\u00a0\u00b5m (95% CI,\u2009\u2212\u200955.4 to\u2009\u2212\u200935.2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), with corresponding reductions in retinal fluid. Anatomical improvements were more pronounced in eyes switched for non-response, whereas more modest but consistent changes were observed in suboptimal and durability-driven groups. Visual and anatomical outcomes were maintained at 6\u00a0months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In previously treated nAMD eyes, switching to aflibercept 8\u00a0mg was associated with reversal of pre-switch anatomical worsening, reduction in retinal fluid, and modest visual gains. Greater responses were observed in eyes with inadequate pre-switch disease control, supporting its role as a treatment escalation strategy in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00417-026-07362-6","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:49:25Z","timestamp":1783320565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching to aflibercept 8\u00a0mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-5348","authenticated-orcid":false,"given":"Daniele","family":"Veritti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0041-5073","authenticated-orcid":false,"given":"Valentina","family":"Sarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-2488","authenticated-orcid":false,"given":"Marco","family":"Lupidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-967X","authenticated-orcid":false,"given":"Pasquale","family":"Viggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-8327","authenticated-orcid":false,"given":"Marco","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-7311","authenticated-orcid":false,"given":"Mariacristina","family":"Parravano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1397-4333","authenticated-orcid":false,"given":"Maria Cristina","family":"Savastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-899X","authenticated-orcid":false,"given":"Giacomo","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2815-5031","authenticated-orcid":false,"given":"Enrico","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5311-5184","authenticated-orcid":false,"given":"Lisa","family":"Toto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0300-4856","authenticated-orcid":false,"given":"Asia Amelia","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5804-4642","authenticated-orcid":false,"given":"Alba Chiara","family":"Termite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Ribezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Nacciarriti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9474-0517","authenticated-orcid":false,"given":"Claudia","family":"Fossataro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni Nikolopoulou","family":"Gisotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7176-9593","authenticated-orcid":false,"given":"Giovanni","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1592-1296","authenticated-orcid":false,"given":"Cesare","family":"Persavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5478-060X","authenticated-orcid":false,"given":"Francesco","family":"Boscia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-5019","authenticated-orcid":false,"given":"Cesare","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1541-4735","authenticated-orcid":false,"given":"Rodolfo","family":"Mastropasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1368-6729","authenticated-orcid":false,"given":"Michele","family":"Reibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-9280","authenticated-orcid":false,"given":"Federico","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-063X","authenticated-orcid":false,"given":"Stanislao","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1575-6567","authenticated-orcid":false,"given":"Alfonso","family":"Savastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6530-1563","authenticated-orcid":false,"given":"Monica","family":"Varano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3746-141X","authenticated-orcid":false,"given":"Paolo","family":"Lanzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"7362_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X et al (2014) Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health 2:e106\u2013e116. https:\/\/doi.org\/10.1016\/S2214-109X(13)70145-1","journal-title":"Lancet Glob Health"},{"key":"7362_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444. https:\/\/doi.org\/10.1056\/NEJMoa062655","journal-title":"N Engl J Med"},{"key":"7362_CR3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431. https:\/\/doi.org\/10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"7362_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V et al (2012) Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548. https:\/\/doi.org\/10.1016\/j.ophtha.2012.09.006","journal-title":"Ophthalmology"},{"key":"7362_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y et al (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72\u201384. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.017","journal-title":"Ophthalmology"},{"key":"7362_CR6","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"7362_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.oret.2019.08.010","volume":"4","author":"TA Ciulla","year":"2020","unstructured":"Ciulla TA, Hussain RM, Pollack JS et al (2020) Visual acuity outcomes and anti-vascular endothelial growth factor therapy intensity in neovascular age-related macular degeneration patients. Ophthalmol Retina 4:19\u201330. https:\/\/doi.org\/10.1016\/j.oret.2019.08.010","journal-title":"Ophthalmol Retina"},{"key":"7362_CR8","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/jcm11020325","volume":"11","author":"D Veritti","year":"2022","unstructured":"Veritti D, Sarao V, Soppelsa V et al (2022) Managing neovascular age-related macular degeneration in clinical practice: systematic review, meta-analysis, and meta-regression. J Clin Med 11:325. https:\/\/doi.org\/10.3390\/jcm11020325","journal-title":"J Clin Med"},{"key":"7362_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamaophthalmol.2018.6796","volume":"137","author":"MC Gillies","year":"2019","unstructured":"Gillies MC, Hunyor AP, Arnold JJ et al (2019) Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol 137:372\u2013379. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.6796","journal-title":"JAMA Ophthalmol"},{"key":"7362_CR10","doi-asserted-by":"publisher","first-page":"3218","DOI":"10.1038\/s41433-024-03055-6","volume":"38","author":"JF Korobelnik","year":"2024","unstructured":"Korobelnik JF, Lanzetta P, Wykoff CC et al (2024) Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases. Eye (Lond) 38:3218\u20133221. https:\/\/doi.org\/10.1038\/s41433-024-03055-6","journal-title":"Eye (Lond)"},{"key":"7362_CR11","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s00417-025-06877-6","volume":"263","author":"D Veritti","year":"2025","unstructured":"Veritti D, Sarao V, Lanzetta P (2025) Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance. Graefes Arch Clin Exp Ophthalmol 263:2985\u20132987. https:\/\/doi.org\/10.1007\/s00417-025-06877-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7362_CR12","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(23)02724-0","volume":"403","author":"P Lanzetta","year":"2024","unstructured":"Lanzetta P, Korobelnik JF, Heier JS et al (2024) Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet 403:1141\u20131152. https:\/\/doi.org\/10.1016\/S0140-6736(23)02724-0","journal-title":"Lancet"},{"key":"7362_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2025.08.012","volume":"133","author":"JF Korobelnik","year":"2026","unstructured":"Korobelnik JF, Lanzetta P, Leal S et al (2026) Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration. Ophthalmology 133:39\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.012","journal-title":"Ophthalmology"},{"key":"7362_CR14","doi-asserted-by":"publisher","first-page":"e17590","DOI":"10.1111\/aos.17590","volume":"103","author":"I Abu Ishkheidem","year":"2025","unstructured":"Abu Ishkheidem I, Inci E, Breimer M et al (2025) Real-world outcomes of aflibercept 8 mg in patients previously treated for neovascular age-related macular degeneration. Acta Ophthalmol 103:e17590. https:\/\/doi.org\/10.1111\/aos.17590","journal-title":"Acta Ophthalmol"},{"key":"7362_CR15","doi-asserted-by":"publisher","first-page":"247412642513833","DOI":"10.1177\/24741264251383384","volume":"9","author":"BA Bates","year":"2025","unstructured":"Bates BA, Mansour HA, Al-khersan H et al (2025) The efficacy and safety of intravitreal aflibercept 8 mg in clinical practice. J Vitreoretin Dis 9:24741264251383384. https:\/\/doi.org\/10.1177\/24741264251383384","journal-title":"J Vitreoretin Dis"},{"key":"7362_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/life15060903","volume":"15","author":"M Musadiq","year":"2025","unstructured":"Musadiq M, Musadiq M, Latif F et al (2025) Early real-world outcomes of switching to 8 mg aflibercept for neovascular age-related macular degeneration in the United Kingdom. Life 15:903. https:\/\/doi.org\/10.3390\/life15060903","journal-title":"Life"},{"key":"7362_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","volume":"29","author":"WM Amoaku","year":"2015","unstructured":"Amoaku WM, Chakravarthy U, Gale R et al (2015) Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond) 29:721\u2013731. https:\/\/doi.org\/10.1038\/eye.2015.48","journal-title":"Eye (Lond)"},{"key":"7362_CR18","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1007\/s00417-025-06912-6","volume":"263","author":"F Eckardt","year":"2025","unstructured":"Eckardt F, Hafner M, Lorger A et al (2025) Efficacy of switching treatment to faricimab in recalcitrant neovascular age-related macular degeneration: 6-month results after completion of the loading phase. Graefes Arch Clin Exp Ophthalmol 263:3053\u20133063. https:\/\/doi.org\/10.1007\/s00417-025-06912-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"7362_CR19","doi-asserted-by":"publisher","first-page":"e002091","DOI":"10.1136\/bmjophth-2024-002091","volume":"10","author":"D Sambhara","year":"2025","unstructured":"Sambhara D, Vakharia P, Eichenbaum DA (2025) Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series. BMJ Open Ophthalmol 10:e002091. https:\/\/doi.org\/10.1136\/bmjophth-2024-002091","journal-title":"BMJ Open Ophthalmol"},{"key":"7362_CR20","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.oret.2025.02.012","volume":"9","author":"S Bala","year":"2025","unstructured":"Bala S, Barbosa GCS, Mohan N et al (2025) Initial functional and anatomical outcomes of high-dose aflibercept 8 mg in exudative neovascular age-related macular degeneration. Ophthalmol Retina 9:756\u2013766. https:\/\/doi.org\/10.1016\/j.oret.2025.02.012","journal-title":"Ophthalmol Retina"},{"key":"7362_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12886-022-02297-9","volume":"22","author":"CK Cheng","year":"2022","unstructured":"Cheng CK, Chen SJ, Chen JT et al (2022) Optimal approaches and criteria to treat-and-extend regimen implementation for neovascular age-related macular degeneration: experts consensus in Taiwan. BMC Ophthalmol 22:25. https:\/\/doi.org\/10.1186\/s12886-022-02297-9","journal-title":"BMC Ophthalmol"},{"key":"7362_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.ophtha.2016.03.048","volume":"123","author":"SM Waldstein","year":"2016","unstructured":"Waldstein SM, Simader C, Staurenghi G et al (2016) Morphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trials. Ophthalmology 123:1521\u20131529. https:\/\/doi.org\/10.1016\/j.ophtha.2016.03.048","journal-title":"Ophthalmology"},{"key":"7362_CR23","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s12325-020-01263-4","volume":"37","author":"M Ohji","year":"2020","unstructured":"Ohji M, Takahashi K, Okada AA et al (2020) Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial. Adv Ther 37:1173\u20131187. https:\/\/doi.org\/10.1007\/s12325-020-01263-4","journal-title":"Adv Ther"},{"key":"7362_CR24","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1097\/IAE.0000000000003146","volume":"41","author":"P Mitchell","year":"2021","unstructured":"Mitchell P, Holz FG, Hykin P et al (2021) Efficacy and safety of intravitreal aflibercept using a treat-and-extend regimen for neovascular age-related macular degeneration: the ARIES study: a randomized clinical trial. Retina 41:1911\u20131920. https:\/\/doi.org\/10.1097\/IAE.0000000000003146","journal-title":"Retina"},{"key":"7362_CR25","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamaophthalmol.2022.1104","volume":"140","author":"NS Patil","year":"2022","unstructured":"Patil NS, Mihalache A, Dhoot AS et al (2022) Association between visual acuity and residual retinal fluid following intravitreal anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: a systematic review and meta-analysis. JAMA Ophthalmol 140:611\u2013619. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.1104","journal-title":"JAMA Ophthalmol"},{"key":"7362_CR26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","volume":"126","author":"RH Guymer","year":"2019","unstructured":"Guymer RH, Markey CM, McAllister IL et al (2019) Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen. Ophthalmology 126:723\u2013734. https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.025","journal-title":"Ophthalmology"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07362-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07362-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07362-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T06:49:26Z","timestamp":1783320566000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07362-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":26,"alternative-id":["7362"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07362-6","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the tenets of the Declaration of Helsinki and was approved by the local Institutional Review Boards of the participating centres according to national regulations governing retrospective observational studies based on routinely collected clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Due to the retrospective nature of the study, informed consent was obtained or waived according to local institutional requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Daniele Veritti: consultant for Bayer, Hofmann La Roche; Valentina Sarao: consultant for Bayer, I-Care, Hofmann La Roche; Pasquale Viggiano: consultant for Abbvie, Bayer, Bausch and Lomb, Hofmann La Roche, Novartis and Zeiss; Mariacristina Parravano: consultant for Abbvie, Bayer, Hofmann La Roche, Novartis, Zeiss; Enrico Borrelli: consultant\/advisor for Abbvie, Bayer, EyePharma, Hofmann La Roche, Novartis, Zeiss. Francesco Boscia: consultant for Alcon, Abbvie, Bayer, Bausch and Lomb, Hofmann La Roche, Novartis and Zeiss. Michele Reibaldi: consultant for Abbvie, Bayer, Hofmann La Roche, Novartis, Zeiss; Monica Varano: consultant for Abbvie, Bayer, Novartis; Paolo Lanzetta: consultant for Aerie, Allergan, Annexon, Apellis, Bausch & Lomb, Bayer, Biogen, Boehringer Ingelheim, EyeBio, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics, and Hofmann La Roche. Marco Lupidi, Marco Lombardo, Giacomo Boscia, Lisa Toto, Asia Amelia Martin, Alba Chiara Termite, Giulia Ribezzi, Enrico Nacciarriti, Eleni Nikolopoulou Gisotti, Giovanni Neri, Cesare Persavalli, Claudia Fossataro, Maria Cristina Savastano, Cesare Mariotti, Rodolfo Mastropasqua, Federico Ricci, Alfonso Savastano, Stanislao Rizzo: none. Enrico Borrelli is a member of the journal\u2019s Editorial Board but had no role in the peer review or editorial decision-making process for this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}